StockNews.AI
ALGS
StockNews.AI
2 hrs

Aligos Therapeutics Reports Recent Business Progress and Third Quarter 2025 Financial Results

1. Aligos's pevifoscorvir sodium study enrolls participants in multiple countries. 2. Interim data for pevifoscorvir sodium expected in 2026. 3. Aligos's cash reserves now at $99.1 million, funding operations until late 2026. 4. Increased R&D expenses due to clinical trial costs. 5. Discussion for funding ALG-055009's obesity treatment ongoing.

12m saved
Insight
Article

FAQ

Why Bullish?

Positive progress in clinical trials and growing cash position can enhance investor confidence.

How important is it?

Strong pipeline advancements and funding place Aligos positively among biotech peers.

Why Long Term?

Phase 2 results in 2026 and potential partnerships could provide future growth.

Related Companies

GILDABBVAMGN
November 06, 2025 08:30 ET  | Source: Aligos Therapeutics SOUTH SAN FRANCISCO, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biotechnology company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today reported recent business progress and financial results for the third quarter 2025. “Our Phase 2 B-SUPREME study of pevifoscorvir sodium (pevy) is enrolling nicely, with subjects dosed across a number of countries, including the U.S., China, Hong Kong, and Canada,” stated Lawrence Blatt, Ph.D., M.B.A., Chairman, President, and Chief Executive Officer of Aligos Therapeutics. “We are pleased with the progress to date and look forward to interim readouts in 2026. Importantly, we look forward to sharing additional pevy data next week at AASLD’s The Liver Meeting®. We maintain our enthusiasm regarding the potential for pevy as well as our entire development pipeline, including ALG-055009, which is in continued discussions with potential partners for obesity and MASH.” Recent Business Progress Pipeline Updates Pevifoscorvir sodium: Potential first-/best-in-class small molecule CAM-E for chronic hepatitis B virus (HBV) infection The Phase 2 B-SUPREME study (NCT06963710) of pevifoscorvir sodium in subjects with chronic HBV infection dosed its first patient in August 2025. The study is designed as a randomized, double-blind, active-controlled multicenter study evaluating the safety and efficacy of pevifoscorvir sodium monotherapy compared with tenofovir disoproxil fumarate in approximately 200 untreated HBeAg+ or HBeAg- adult subjects with chronic HBV infection for 48 weeks. The primary endpoint in the HBeAg+ subjects is HBV DNA

Related News